Last reviewed · How we verify
NCT06842407: Immuno-ab
Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
trial in Healthy Donors in 600 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | Checkmab S.r.l. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 1 April 2023 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across Italy |
Conditions studied
- Healthy Donors — all drugs for Healthy Donors →
Sponsor
Checkmab S.r.l.
Who can join
18 and older, any sex, with Healthy Donors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06842407
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Donors
Currently open trials in the same condition.
- NCT06834451 — Bioequivalence Study of Revolade® Eltrombopag 50 mg · Phase 4 · active not recruiting
- NCT06738329 — Investigating the Impact of the Seaweed Derived Food Additive, Carrageenan, on the Human Gut Microbiome · NA · recruiting
- NCT06861842 — Bioequivalence Study of Lithium Carbonate 300 mg Tablets. Actilitio® in Healthy Subjects · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06842407 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Checkmab S.r.l.
- Last refreshed: 24 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06842407.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing